Need help? Order a test

Developing and providing personalised cancer tests for doctors and patients

More about RGCC
Scroll down

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Cancer tests

New methods and reliable tests to help deliver personalised treatment

RGCC CAMBISeq™

RGCC CAMBISeq (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.

View test

Array comparative genomic hybridisation (aCGH) RGCC

This test identifies chromosomal abnormalities – when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer. It uses a technique called array CGH to identify abnormalities in a genome more clearly than traditional microscopes can. These abnormalities could be linked with parts of regions […]

View test

Immune-Frame

This test focuses on the status of a patient’s immune system. The test uses specific cellular markers, and the production of proteins called cytokines, to detect the type or types of cells that are responsible for switching a patient’s immune system on and off. Immune-Frame uses two different assays: the ELISA assay is used to […]

View test

Metastat RGCC

This test provides information, based on the detection of circulating tumour cells, about whether and where the tumour is likely to spread. Studies show that the cancer cells that have the potential to spread from the primary tumour express specific genes and proteins, or markers. These markers vary according to the organ that the tumour […]

View test

ChemoSNiP

This test relies on pharmacogenomics. This is the science of inherited variations in genes, how these inherited variations dictate a patient’s response to a drug, and the ways these variations can be used to predict whether a patient will have a good or bad response to a drug, or no response at all. ChemoSNiP tests […]

View test

Onconomics Extracts

This test provides information about the efficacy of natural biological substances or extracts on circulating tumour cells. Onconomics Extracts focuses on testing using three methods: testing for the direct effect of an anti-cancer treatment, stimulating the immune system and inhibiting proliferative signals in the cancer cells that stimulate them to grow.

View test

Onconomics Plus RGCC

This test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. Onconomics Plus RGCC is based on three methods: testing for the direct effect […]

View test

Onconomics RGCC

This test provides information about the effect of specific anti-cancer drugs and targeted therapies on a single patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays.

View test

Oncotrail RGCC

This test provides information about the presence of circulating tumour cells, their concentration, and immunophenotype for specific types of malignancies. This test is a tailor-made test for certain cancers: such as breast cancer (for which we provide the Oncotrail RGCC for breast cancer) and prostate cancer (for which we provide Oncotrail RGCC for prostate cancer. […]

View test

Oncotrace RGCC

This test provides information about the presence of circulating tumour cells, and their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

View test

Oncocount RGCC

This test detects the presence of circulating tumour cells, and measures their concentration in the blood. As these cells that could lead to the recurrence of a cancer, this test is useful to detect relapse early, and as a follow-up tool.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

New test could spot early signs of prostate cancer

Researchers have used genetic testing to detect the very early changes that occur in the tumours of men with prostate cancer. Researchers at the University College London (UCL) Cancer Institute say the new type of blood test will help them understand the genetic characteristics of the tumours that cause prostate cancer, which is the second […]

Read more

Study shows genetic changes can occur years before diagnosis

A study suggests the genetic changes that cause cancers can happen years or even decades before the disease is diagnosed. A large analysis by an international team of researchers revealed that many DNA mutations – the changes in our genome that can trigger a tumour to develop – can occur long before someone is diagnosed […]

Read more

Clinical CTC Seminar in Tokyo, Japan

On January 2020 took place the in Tokyo the Clinical CTC Seminar. This event was promoted by Dr. Atsushi Yanagisawa, Chairman of the Intravenous Therapy Study Group and Dr. Kunihiro Kitamura, Director of the Kitamura Clinic in Fukuoka. Dr. Ioannis Papasotiriou was one of the basics lecturer.

Read more

Circulating tumour DNA tests predictive in pancreatic cancer

More evidence is emerging to support the use of testing for circulating tumour DNA (ctDNA) as a promising way to predict whether a cancer will come back. Tumours release degraded fragments of DNA, including ctDNA, into the bloodstream. Testing a cancer patient’s blood for this DNA, using a type of blood test called a liquid […]

Read more

Liquid biopsy potential to guide colorectal cancer treatment

In the future, liquid biopsy testing is likely to play an increasing role in identifying which patients with colorectal cancer are most likely to have their cancer come back again after surgery. Liquid biopsy testing could also help doctors to decide which treatments would be most suitable to recommend to individual patients, according to new […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more